Navigation Links
NIH neuroscience microarray consortium launches high-throughput genotyping services

The NIH Neuroscience Microarray Consortium today announced that it has added high-density genotyping on both the Affymetrix and Illumina platforms to its list of services. Stan Nelson, the principal investigator at UCLA, says that "adding ultra-high throughput genotyping for its user-base of ~10,000 investigators across the world keeps the Consortium current with the demands of the scientific community."

The Consortium is comprised of four nationally recognized centers located at Duke University in Durham, NC, the Translational Genomics Research Institute (TGen) in Phoenix, AZ, the University of California in Los Angeles, and Yale University in New Haven, CT. The Consortium can be accessed through its web portal at http://arrayconsortium.tgen.org.

Initially funded in 2002 by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute of Mental Health (NIMH), the Microarray Consortium is now supported by these two institutes as well as the thirteen other NIH Neuroscience Blueprint institutes and centers.

"The consortium that we have established over the past four years is a nation-wide technology outlet that dramatically accelerates the pace of neuroscience research," said Consortium Chairman Dr. Dietrich Stephan, who is also the director of TGen's Neurogenomics Division. "Implementing these high throughput genotyping services will ultimately make a dramatic impact in clinical care of neurological disorders."

About 10,000 investigators funded through the 15 different NIH institutes are part of the NIH Neuroscience Blueprint and have access to the technology and expertise within the national Consortium. "Now," says Pate Skene, the PI at Duke University, "scientists investigating any aspect of the brain, behavior or neurological disease have access to a full range of microarray technologies for scanning the entire human genome and all of the genes f or which it encodes."

Each of the four members of the Consortium offer specialized services. The Translational Genomics Research Institute (TGen) offers both expression profiling and SNP genotyping on Affymetrix Genechips. UCLA, in addition to the Affymetrix platform, processes Agilent arrays; Duke offers LCM services, Ambion mirVana arrays, and Operon oligo arrays; Yale offers expression profiling and genotyping on the Affymetrix platform and uses the Affymetrix exon arrays to look at splice variants, in addition to the new Illumina expression and genotyping capabilities.

The principal investigator at Yale, Shrikant Mane, says that the "Illumina platform provides an important complement to the other technologies currently available through the NIH Neuroscience Microarray Consortium and will significantly aid the research goals of the neuroscientist."


'"/>

Source:The Translational Genomics Research Institute


Related biology news :

1. An entropy-based gene selection method for cancer classification using microarray data
2. Genrate: a generative model that finds and scores new genes and exons in genomic microarray data
3. Different microarray systems more alike than previously thought
4. Agilent Technologies releases probe sequence, annotation information for all its commercial gene expression microarrays
5. Agilent Technologies introduces advanced zebrafish, mouse microarrays for stem cell and developmental biology research
6. Carnegie Mellon U. transforms DNA microarrays with standard Internet communications tool
7. Chromosomal microarray analysis proves accurate
8. International HapMap consortium expands mapping effort
9. Autism gene identified by researchers at Yale working with a global research consortium
10. UCLA launches $20 million stem cell institute to investigate HIV, cancer and neurological disorders
11. UNC launches study of liver injury caused by drugs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/29/2016)... BOSTON , Nov. 29, 2016 BioDirection, ... rapid point-of-care products for the objective detection of concussion ... the company has successfully completed a meeting with the ... company,s Tbit™ blood test Pre-Submission Package. During the meeting ... Tbit™ system as a precursor to commencement of a ...
(Date:11/28/2016)... -- "The biometric system market projected ... biometric system market is in the growth stage and ... The biometric system market is expected to be valued ... of 16.79% between 2016 and 2022. Government initiative in ... smartphones, rising use of biometric technology in financial institutes ...
(Date:11/22/2016)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce that the company has been ... Awards as "Most Outstanding in eClinical Solutions" for ... recognition and growth for MedNet, which has effectively supported ... iMedNet ™ , MedNet,s flagship eClinical technology ...
Breaking Biology News(10 mins):
(Date:12/5/2016)... CALGARY , Dec. 5, 2016 /PRNewswire/ - ... announced  that the independent Data and Safety Monitoring ... trial in high-risk cardiovascular disease (CVD) patients has ... that the study should continue as planned without ... and noted that no safety or efficacy concerns ...
(Date:12/5/2016)... Dec. 5, 2016  Eisai Inc. announced today ... study of rufinamide, which were presented at the ... (AES) held from December 2-6 in ... safety, tolerability and cognitive data showed that patients ... safety and tolerability profiles, cognitive development and behavior, ...
(Date:12/5/2016)... -- The U.S. Biotechnology industry is the ... revenue and some $890 billion of total market value. In ... and this figure is expected to exceed $220 billion ... four equities for assessment: Northwest Biotherapeutics Inc. (NASDAQ: ... ACAD ), Acorda Therapeutics Inc. (NASDAQ: ACOR ...
(Date:12/4/2016)... ... 03, 2016 , ... Microbial genomics leader uBiome is awarding ... been made to Dr. Renato Polimanti of Yale University School of Medicine, who ... Grant proposals have been vetted by the company’s scientific review committee. , ...
Breaking Biology Technology: